TORONTO and HAIFA, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a ...
Pandorum Technologies, a clinical-stage regenerative medicine company building a next-generation platform for programmable tissue regeneration, today announced a strategic collaboration with Hyderabad ...
This milestone marks a pivotal point in Avalon's pipeline, now allowing the company to enter its next phase of commercializing clinical-grade exosome products FREEHOLD, New Jersey, June 10, 2019 ...
TORONTO and HAIFA, Israel, Aug. 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (NRX:CA), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”) is pleased to announce significant ...
The cell and gene therapy industry will greatly benefit from access to robust, scalable, end-to-end solutions for the production and characterization of native and engineered exosome therapeutics.” — ...
Exosomes are a population of naturally occurring mobile, membrane-limited, 30 – 100 nm in diameter, extracellular vesicles containing a large number of proteins, lipids, messenger, and micro-RNAs. It ...
Bengaluru's Pandorum Technologies teams up with Nucelion Therapeutics to scale its exosome-based therapeutic platform across ...
PARIS--(BUSINESS WIRE)--EVerZom, a biopharmaceutical company specialized in the bioproduction of exosomes, announced today that it has raised €1.1 million in funding from institutional and private ...
After retinol, collagen, peptides, and other beauty trends, the newest intrigue on the block is exosome therapy. Used for both skin and hair, it's less a supplement you pop and more a science-driven, ...
FREEHOLD, N.J., June 10, 2019 /PRNewswire/ -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, today announced it has achieved a major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback